News | July 27, 2021
GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year
Growth was broad-based across segments
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The company reported net revenue of SEK 13.5 million for the full year 2025
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Subscribe To Our Newsletter & Stay Updated
